An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer-Reference-Cited by-同舟云学术

An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer

Published:2015-06-12 Issue:9 Volume:24 Page:1143-1161
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Pilotto Sara,Novello Silvia,Peretti Umberto,Kinspergher Stefania,Ciuffreda Ludovica,Milella Michele,Carbognin Luisa,Vavalà Tiziana,Ferrara Roberto,Caccese Mario,Tortora Giampaolo,Bria Emilio

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.2015.1056341

Reference125 articles.

1. The Hallmarks of Cancer

2. Hallmarks of Cancer: The Next Generation

3. Tumorigenesis and the angiogenic switch

4. The angiogenic switch in carcinogenesis

5. Angiogenesis in pre-malignant conditions

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma;The Oncologist;2022-04-21

2. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib‐resistant ALK mutations;Journal of Cellular Biochemistry;2018-09-06

3. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system;Expert Review of Molecular Diagnostics;2017-10-23

4. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer;Oncotarget;2017-01-11

5. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes;Journal of Thoracic Oncology;2016-07